γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct

γ‐Secretase inhibitors (GSIs) are being actively repurposed as cancer therapeutics based on the premise that inhibition of NOTCH1 signaling in select cancers is therapeutic. Using novel assays to probe effects of GSIs against a broader panel of substrates, we demonstrate that clinical GSIs are pharm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EMBO Mol Med
Main Authors: Ran, Yong, Hossain, Fokhrul, Pannuti, Antonio, Lessard, Christian B, Ladd, Gabriela Z, Jung, Joo In, Minter, Lisa M, Osborne, Barbara A, Miele, Lucio, Golde, Todd E
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5494507/
https://ncbi.nlm.nih.gov/pubmed/28539479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201607265
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados